Roberto A. Leon‐Ferre

2.7k total citations · 1 hit paper
53 papers, 989 citations indexed

About

Roberto A. Leon‐Ferre is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Roberto A. Leon‐Ferre has authored 53 papers receiving a total of 989 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 23 papers in Cancer Research and 13 papers in Genetics. Recurrent topics in Roberto A. Leon‐Ferre's work include Breast Cancer Treatment Studies (15 papers), Cancer Immunotherapy and Biomarkers (10 papers) and HER2/EGFR in Cancer Research (9 papers). Roberto A. Leon‐Ferre is often cited by papers focused on Breast Cancer Treatment Studies (15 papers), Cancer Immunotherapy and Biomarkers (10 papers) and HER2/EGFR in Cancer Research (9 papers). Roberto A. Leon‐Ferre collaborates with scholars based in United States, Sweden and Canada. Roberto A. Leon‐Ferre's co-authors include Matthew P. Goetz, Judy C. Boughey, Tina J. Hieken, Fergus J. Couch, Kathryn J. Ruddy, Karthik V. Giridhar, Charles L. Loprinzi, Robert W. Mutter, John R. Hawse and Antonino B. D’Assoro and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Roberto A. Leon‐Ferre

50 papers receiving 976 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advances in systemic therapies for triple negative breast cancer

2023 259 citations Roberto A. Leon‐Ferre, Matthew P. Goetz profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roberto A. Leon‐Ferre United States	15	447	284	275	199	176	53	989
Siddhartha Deb Australia	20	435 1.0×	244 0.9×	660 2.4×	183 0.9×	229 1.3×	48	1.3k
Thorunn Helgason United States	15	427 1.0×	342 1.2×	467 1.7×	131 0.7×	213 1.2×	31	1.1k
Karthik V. Giridhar United States	13	192 0.4×	167 0.6×	294 1.1×	182 0.9×	142 0.8×	63	677
Synnöve Staff Finland	20	429 1.0×	172 0.6×	454 1.7×	158 0.8×	79 0.4×	48	1.2k
Andrew P. Sciallis United States	15	254 0.6×	172 0.6×	225 0.8×	67 0.3×	162 0.9×	39	770
Yacine Barèche Belgium	14	600 1.3×	356 1.3×	321 1.2×	68 0.3×	197 1.1×	24	1.0k
Timothy P. Heffernan United States	18	476 1.1×	378 1.3×	837 3.0×	50 0.3×	137 0.8×	38	1.3k
Giuseppe Gullo Ireland	13	368 0.8×	154 0.5×	271 1.0×	66 0.3×	151 0.9×	42	692
Eleftherios Pierre Samartzis Switzerland	24	338 0.8×	133 0.5×	500 1.8×	167 0.8×	88 0.5×	43	1.3k
Martina Álvarez Spain	13	523 1.2×	281 1.0×	247 0.9×	67 0.3×	135 0.8×	41	840

Countries citing papers authored by Roberto A. Leon‐Ferre

Since Specialization

Citations

This map shows the geographic impact of Roberto A. Leon‐Ferre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto A. Leon‐Ferre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto A. Leon‐Ferre more than expected).

Fields of papers citing papers by Roberto A. Leon‐Ferre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto A. Leon‐Ferre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto A. Leon‐Ferre. The network helps show where Roberto A. Leon‐Ferre may publish in the future.

Co-authorship network of co-authors of Roberto A. Leon‐Ferre

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto A. Leon‐Ferre. A scholar is included among the top collaborators of Roberto A. Leon‐Ferre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto A. Leon‐Ferre. Roberto A. Leon‐Ferre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leon‐Ferre, Roberto A., Christina Yau, Gillian L. Hirst, et al.. (2025). Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial. Breast Cancer Research. 27(1). 115–115. 1 indexed citations

Hoskin, Tanya L., et al.. (2025). The Association of Clinical Stage at Presentation with Overall Survival of Patients who have HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy. Annals of Surgical Oncology. 32(13). 9798–9806.

Leon‐Ferre, Roberto A., Jodi M. Carter, David M. Zahrieh, et al.. (2024). Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer. npj Breast Cancer. 10(1). 25–25. 1 indexed citations

Jahan, Nusrat, Nicholas Boddicker, Karthik V. Giridhar, et al.. (2024). Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic Experience. Clinical Breast Cancer. 25(3). e211–e219.e2.

Haddad, Tufia C., Vera J. Suman, Karthik V. Giridhar, et al.. (2024). Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial. Clinical Cancer Research. 30(15). 3147–3156. 3 indexed citations

Geist, Felix, Xiaojia Tang, Krishna R. Kalari, et al.. (2024). Identification of a Notch transcriptomic signature for breast cancer. Breast Cancer Research. 26(1). 4–4. 4 indexed citations

Budhathoki, Pravash, Anurag Adhikari, Grace M. Choong, et al.. (2023). Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast. Breast Cancer Research and Treatment. 200(2). 217–224. 7 indexed citations

Yadav, Siddhartha, Lindsey R. Sangaralingham, Stephanie Payne, et al.. (2022). Surveillance mammography after treatment for male breast cancer. Breast Cancer Research and Treatment. 194(3). 693–698. 1 indexed citations

Thompson, Kevin J., Roberto A. Leon‐Ferre, Jason P. Sinnwell, et al.. (2022). Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. NAR Cancer. 4(2). zcac018–zcac018. 26 indexed citations

10.

Leon‐Ferre, Roberto A., Tina J. Hieken, & Judy C. Boughey. (2021). The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. Annals of Surgical Oncology. 28(4). 2111–2119. 59 indexed citations

11.

Carter, Jodi M., Mei‐Yin C. Polley, Roberto A. Leon‐Ferre, et al.. (2021). Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer. Clinical Cancer Research. 27(20). 5628–5637. 35 indexed citations

12.

Yadav, Siddhartha, Karthik V. Giridhar, José Pablo Leone, Roberto A. Leon‐Ferre, & Kathryn J. Ruddy. (2021). A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer. SHILAP Revista de lepidopterología. 10(3). 4 indexed citations

13.

Cathcart-Rake, Elizabeth, Paul J. Novotny, Roberto A. Leon‐Ferre, et al.. (2020). A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. Supportive Care in Cancer. 29(1). 387–396. 11 indexed citations

14.

Carter, Jodi M., Mei‐Yin C. Polley, Jason P. Sinnwell, et al.. (2020). Abstract PD1-08: Frequency, characteristics and prognostic factors of PD-L1+ triple negative breast cancer using the PD-L1 SP142 companion assay. Cancer Research. 80(4_Supplement). PD1–8. 3 indexed citations

15.

Yadav, Siddhartha, et al.. (2020). Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences?. Expert Opinion on Drug Safety. 19(8). 923–926. 3 indexed citations

16.

Yadav, Siddhartha, Irbaz Bin Riaz, Hao Xie, et al.. (2019). Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer. 126(1). 26–36. 90 indexed citations

17.

Leon‐Ferre, Roberto A., Paul J. Novotny, Eric Wolfe, et al.. (2019). Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI Cancer Spectrum. 4(1). pkz088–pkz088. 52 indexed citations

18.

Leon‐Ferre, Roberto A., Karthik V. Giridhar, Tina J. Hieken, et al.. (2018). A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer and Metastasis Reviews. 37(4). 599–614. 55 indexed citations

19.

Leon‐Ferre, Roberto A., Mei‐Yin C. Polley, Heshan Liu, et al.. (2017). Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Research and Treatment. 167(1). 89–99. 73 indexed citations

20.

Leon‐Ferre, Roberto A., Boris G. Naraev, Anna M. Button, et al.. (2012). Clinical outcomes and predictive value of chromogranin A (CgA) and pancreastatin (PcSt) in liver-directed therapies (LDTs) for well-differentiated metastatic neuroendocrine tumors.. Journal of Clinical Oncology. 30(15_suppl). e14620–e14620. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact